Heli Skottman’s Eye group at Tampere University has worked with human pluripotent stem cells (hPSCs) for over a decade, with the aim to develop stem cell based tools for corneal and retinal therapies and disease models.

Building on the group’s expertise in cell biology, biomaterial engineering and genetics, we are preparing to launch a new cell therapy product for the treatment of corneal limbal stem cell deficiency, based on allogenic limbal stem cells obtained through differentiation from hPSCs.